Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial

View ORCID ProfileSusan M Bueno, View ORCID ProfileKatia Abarca, Pablo A González, View ORCID ProfileNicolás MS Gálvez, Jorge A Soto, View ORCID ProfileLuisa F Duarte, View ORCID ProfileBárbara M Schultz, View ORCID ProfileGaspar A Pacheco, Liliana A González, Yaneisi Vázquez, Mariana Ríos, Felipe Melo-González, Daniela Rivera-Pérez, Carolina Iturriaga, Marcela Urzúa, Angélica Dominguez, View ORCID ProfileCatalina A Andrade, Roslye V Berrios, Gisela Canedo-Marroquín, Camila Covián, Daniela Moreno-Tapia, View ORCID ProfileFarides Saavedra, Omar P Vallejos, Paulina Donato, Pilar Espinoza, Daniela Fuentes, Marcela González, Paula Guzmán, Paula Muñoz-Venturelli, Carlos M Pérez, Marcela Potin, Alvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Aarón Oyarzún-Arrau, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alessandro Sette, Gang Zeng, Weining Meng, José V González-Aramundiz, View ORCID ProfileAlexis M Kalergis
doi: https://doi.org/10.1101/2021.03.31.21254494
Susan M Bueno
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susan M Bueno
  • For correspondence: akalergis@bio.puc.cl sbueno@bio.puc.cl
Katia Abarca
1Millennium Institute on Immunology and Immunotherapy
3Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katia Abarca
Pablo A González
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolás MS Gálvez
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicolás MS Gálvez
Jorge A Soto
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa F Duarte
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luisa F Duarte
Bárbara M Schultz
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bárbara M Schultz
Gaspar A Pacheco
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gaspar A Pacheco
Liliana A González
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaneisi Vázquez
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Ríos
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felipe Melo-González
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Rivera-Pérez
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Iturriaga
3Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcela Urzúa
3Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angélica Dominguez
4Departamento de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catalina A Andrade
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catalina A Andrade
Roslye V Berrios
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisela Canedo-Marroquín
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camila Covián
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Moreno-Tapia
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farides Saavedra
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Farides Saavedra
Omar P Vallejos
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulina Donato
5Complejo Asistencial Dr. Sótero del Rio, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pilar Espinoza
6Hospital Clínico Félix Bulnes
7Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Fuentes
8Hospital Carlos Van Buren, V Región, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcela González
9Hospital Dr. Gustavo Fricke, V Región, Chile
10Departamento de Pediatría, Universidad de Valparaíso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Guzmán
11Clínica Los Andes, Universidad de Los Andes, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Muñoz-Venturelli
12Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos M Pérez
6Hospital Clínico Félix Bulnes
7Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcela Potin
13Clínica San Carlos de Apoquindo, Red de Salud UC Christus, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvaro Rojas
14Departamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodrigo Fasce
15Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Fernández
15Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Mora
15Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugenio Ramírez
15Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aracelly Gaete-Argel
16Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aarón Oyarzún-Arrau
16Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Valiente-Echeverría
16Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Soto-Rifo
16Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Weiskopf
17Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Sette
17Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Zeng
18Sinovac Biotech, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weining Meng
18Sinovac Biotech, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José V González-Aramundiz
19Departamento de Farmacia, Facultad de Química y de Farmacia. Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexis M Kalergis
1Millennium Institute on Immunology and Immunotherapy
2Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
20Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexis M Kalergis
  • For correspondence: akalergis@bio.puc.cl sbueno@bio.puc.cl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.

Methods This is a multicenter phase 3 clinical trial. Healthcare workers aged 18 years and older were randomly assigned to receive two doses of CoronaVac or placebo separated by two weeks (0-14). We report preliminary safety results obtained for a subset of 434 participants, and antibody and cell-mediated immunity results obtained in a subset of participants assigned to the immunogenicity arm. The primary and secondary aims of the study include the evaluation of safety parameters and immunogenicity against SARS-CoV-2 after immunization, respectively. This trial is registered at clinicaltrials.gov (NCT04651790).

Findings The recruitment of participants occurred between November 27th, 2020, until January 9th, 2021. 434 participants were enrolled, 397 were 18-59 years old, and 37 were ≥60 years old. Of these, 270 were immunized with CoronaVac, and the remaining 164 participants were inoculated with the corresponding placebo. The primary adverse reaction was pain at the injection site, with a higher incidence in the vaccine arm (55.6%) than in the placebo arm (40.0%). Moreover, the incidence of pain at the injection site in the 18-59 years old group was 58.4% as compared to 32.0% in the ≥60 years old group. The seroconversion rate for specific anti-S1-RBD IgG was 47.8% for the 18-59 years old group 14 days post immunization (p.i.) and 95.6% 28 and 42 days p.i. For the ≥60 years old group, the seroconversion rate was 18.1%, 100%, and 87.5% at 14, 28, and 42 days p.i., respectively. Importantly, we observed a 95.7% seroconversion rate in neutralizing antibodies for the 18-59 years old group 28 and 42 days p.i. The ≥60 years old group exhibited seroconversion rates of 90.0% and 100% at 28 and 42 days p.i. Interestingly, we did not observe a significant seroconversion rate of anti-N-SARS-CoV-2 IgG for the 18-59 years old group. For the participants ≥60 years old, a modest rate of seroconversion at 42 days p.i. was observed (37.5%). We observed a significant induction of a T cell response characterized by the secretion of IFN-γ upon stimulation with Mega Pools of peptides derived from SARS-CoV-2 proteins. No significant differences between the two age groups were observed for cell-mediated immunity.

Interpretation Immunization with CoronaVac in a 0-14 schedule in adults of 18 years and older in the Chilean population is safe and induces specific IgG production against the S1-RBD with neutralizing capacity, as well as the activation of T cells secreting IFN-γ, upon recognition of SARS-CoV-2 antigens.

Funding Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.

Competing Interest Statement

A.S. is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead and Avalia. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.

Clinical Trial

NCT04651790

Funding Statement

Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was conducted according to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki, and local regulations. The trial protocol was reviewed and approved by the Institutional Scientific Ethical Committee of Health Sciences, Pontificia Universidad Catolica de Chile, Approval #200708006 (Committee members: Claudia Uribe PUC/Committee president; Colomba Cofre/Committee Vice-president; Andrea Villagran/Executive secretary; Jorge Munoz/External Lawyer; Gustavo Kaltwasser/External member; Alysa Garay/Community representative; Marisa Torres/Public Health Department; Carolina Mendez/Speech therapy representative; Luis Villarroel/Public Health Department; Pablo Brockman/Respiratory Diseases in Children Department. Website: http://eticayseguridad.uc.cl/comite-etico-cientifico-facultad-de-medicina-uc.html). Trial execution was approved by the Chilean Public Health Institute (#24204/20).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the data included in the manuscript is available upon request to the corresponding authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 01, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
Susan M Bueno, Katia Abarca, Pablo A González, Nicolás MS Gálvez, Jorge A Soto, Luisa F Duarte, Bárbara M Schultz, Gaspar A Pacheco, Liliana A González, Yaneisi Vázquez, Mariana Ríos, Felipe Melo-González, Daniela Rivera-Pérez, Carolina Iturriaga, Marcela Urzúa, Angélica Dominguez, Catalina A Andrade, Roslye V Berrios, Gisela Canedo-Marroquín, Camila Covián, Daniela Moreno-Tapia, Farides Saavedra, Omar P Vallejos, Paulina Donato, Pilar Espinoza, Daniela Fuentes, Marcela González, Paula Guzmán, Paula Muñoz-Venturelli, Carlos M Pérez, Marcela Potin, Alvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Aarón Oyarzún-Arrau, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alessandro Sette, Gang Zeng, Weining Meng, José V González-Aramundiz, Alexis M Kalergis
medRxiv 2021.03.31.21254494; doi: https://doi.org/10.1101/2021.03.31.21254494
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
Susan M Bueno, Katia Abarca, Pablo A González, Nicolás MS Gálvez, Jorge A Soto, Luisa F Duarte, Bárbara M Schultz, Gaspar A Pacheco, Liliana A González, Yaneisi Vázquez, Mariana Ríos, Felipe Melo-González, Daniela Rivera-Pérez, Carolina Iturriaga, Marcela Urzúa, Angélica Dominguez, Catalina A Andrade, Roslye V Berrios, Gisela Canedo-Marroquín, Camila Covián, Daniela Moreno-Tapia, Farides Saavedra, Omar P Vallejos, Paulina Donato, Pilar Espinoza, Daniela Fuentes, Marcela González, Paula Guzmán, Paula Muñoz-Venturelli, Carlos M Pérez, Marcela Potin, Alvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Aarón Oyarzún-Arrau, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alessandro Sette, Gang Zeng, Weining Meng, José V González-Aramundiz, Alexis M Kalergis
medRxiv 2021.03.31.21254494; doi: https://doi.org/10.1101/2021.03.31.21254494

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (942)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8969)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1322)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10768)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1818)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4109)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (363)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)